Conjugated Via Claimed Linking Group, Bond, Chelating Agent, Or Coupling Agent (e.g., Conjugated To Proteinaceous Toxin Via Claimed Linking Group, Bond, Coupling Agent, Etc.) Patents (Class 424/179.1)
-
Patent number: 9181235Abstract: The present invention relates to compositions and methods for modulating the Wnt signaling pathway, using compounds having Formula (1) and (3): wherein A, B, Y and Z all represent rings, and R1, R2, R3 are as defined herein.Type: GrantFiled: June 28, 2011Date of Patent: November 10, 2015Assignee: NOVARTIS AGInventors: Dai Cheng, Guobao Zhang, Dong Han, Wenqi Gao, Shifeng Pan, Lichun Shen, Rajender Reddy Leleti
-
Patent number: 9102730Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.Type: GrantFiled: April 29, 2013Date of Patent: August 11, 2015Assignee: Baylor Research InstituteInventors: Gerard Zurawski, Jacques F. Banchereau, Eynav Klechevsky, Sandra Zurawski, Anne-Laure Flamar
-
Patent number: 9044518Abstract: The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.Type: GrantFiled: March 29, 2012Date of Patent: June 2, 2015Assignee: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITYInventors: George R. Pettit, Fiona Hogan, Steven Toms
-
Publication number: 20150139947Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: ApplicationFiled: October 31, 2014Publication date: May 21, 2015Applicant: BIOGEN IDEC HEMOPHILIA INC.Inventors: ROBERT T. PETERS, ADAM R. MEZO, DANIEL S. RIVERA, ALAN J. BITONI, SUSAN C. LOW
-
Publication number: 20150140022Abstract: A compound comprising a photosensitizer covalently coupled to a protein selected from the group consisting of antibodies or their derivatives or fragments thereof, synthetic peptides such as scFv, mimotopes which bind CD antigens, cytokine receptors, interleukin receptors, hormone receptors, growth factor receptors, more particularly tyrosine kinase growth factor receptor of the ErbB family, wherein the photosensitizer is coupled to the binding protein via O6-alkylguanine-DNA alkyltransferase (hAGTm), a modified human DNA repair protein.Type: ApplicationFiled: March 21, 2012Publication date: May 21, 2015Inventors: Stefan Barth, Mehmet K. Tur, Ahmad Hussain
-
Publication number: 20150132324Abstract: Tubulysin compounds of the formula (I) where R1, R2, R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.Type: ApplicationFiled: January 26, 2015Publication date: May 14, 2015Inventors: Qiang CONG, Heng Cheng, Sanjeev Gangwar
-
Patent number: 9028833Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.Type: GrantFiled: July 23, 2013Date of Patent: May 12, 2015Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Publication number: 20150125473Abstract: The present invention concerns a process for the preparation of an antibody conjugate comprising the step of reacting an engineered antibody having a single inter-heavy chain disulfide bond with a conjugating reagent that forms a bridge between the two cysteine residues derived from the disulfide bond.Type: ApplicationFiled: June 19, 2013Publication date: May 7, 2015Inventors: John Burt, Antony Godwin, George Badescu
-
Publication number: 20150125474Abstract: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.Type: ApplicationFiled: October 10, 2014Publication date: May 7, 2015Inventors: Roger A. Smith, Nitin K. Damle, Aleksandr V. Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Cheri A. Stevenson, Venu R. Gurijala
-
Patent number: 9023356Abstract: The present invention relates to the treatment of EGFR-mediated disease, particularly cancer by inhibiting or blocking EGFR and src in combination or simultaneously. The invention relates to treatment, prevention, or modulation of cancer, particularly EGFR-mediated disease, with one or more EGFR modulator and src inhibitor in combination. The invention further relates to the treatment of cancer with anti-EGFR antibodies and src inhibitors. Methods and compositions for treatment of cancer with the antibody anti-EGFR mAb806 in combination or series with a src inhibitor or src inhibitors are described.Type: GrantFiled: March 14, 2008Date of Patent: May 5, 2015Assignees: Ludwig Institute for Cancer Research Ltd, The Regents of the University of CaliforniaInventors: Terrance Grant Johns, Webster Cavenee, Frank Furnari, Andrew Scott
-
Publication number: 20150118185Abstract: Compositions containing conjugates of heparosan polymer with at least one drug are disclosed, along with methods of production and use thereof.Type: ApplicationFiled: November 7, 2014Publication date: April 30, 2015Inventor: Paul L. DeAngelis
-
Publication number: 20150104468Abstract: The present disclosure provides methods of site-specific labeling of antibodies, using proteins having 4?-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates.Type: ApplicationFiled: May 31, 2013Publication date: April 16, 2015Applicant: IRM LLCInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Badry Bursulaya
-
Publication number: 20150104383Abstract: The invention provides methods and compositions employing hybrid molecules of a synthetic molecule and antibody or antibody fragment comprising a selenocysteine residue, wherein the synthetic molecule is covalently linked to the antibody or antibody fragment at the selenocysteine residue. The invention also provides a composition comprising a hybrid molecule as described above and a pharmaceutically acceptable carrier. The invention further provides for methods of making the hybrid molecules, and methods of using the hybrid molecule described above to inhibit cell surface receptor binding.Type: ApplicationFiled: December 22, 2014Publication date: April 16, 2015Inventors: Christoph Rader, Thomas Hofer, Terrence R. Burke, JR., Joshua Thomas
-
Patent number: 9005625Abstract: The present invention provides conjugates formed between toxins and sugars and toxins and peptides, such as antibodies. In an exemplary embodiment, a toxin-sugar construct is conjugated to an antibody through an intact glycosyl linking group.Type: GrantFiled: July 26, 2004Date of Patent: April 14, 2015Assignee: Novo Nordisk A/SInventors: Shawn DeFrees, Zhi-Guang Wang
-
Patent number: 8992932Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practiced as a monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: October 20, 2012Date of Patent: March 31, 2015Assignee: Seattle Genetics, Inc.Inventors: Hans-Georg Lerchen, Lars Linden, Sherif El Sheikh, Jörg Willuda, Charlotte Christine Kopitz, Joachim Schuhmacher, Simone Greven, Christoph Mahlert, Beatrix Stelte-Ludwig, Sven Golfier, Rudolf Beier, Iring Heisler, Axel Harrenga, Karl-Heinz Thierauch, Sandra Bruder, Heike Petrul, Hannah Jöriβen, Sandra Borkowski
-
Publication number: 20150086576Abstract: In some aspects, polypeptides comprising single domain antibodies and methods of identifying single domain antibodies are provided. In some embodiments polypeptides comprising a single domain antibody and a sortase recognition sequence, are provided. In some aspects, products and methods of use in modulating the immune system, e.g., modulating an immune response, are provided.Type: ApplicationFiled: April 15, 2013Publication date: March 26, 2015Inventors: Hidde Ploegh, Maximilian Popp, Juanjo Cragnolini
-
Patent number: 8986699Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a carrier such as a polymer, nanoparticle, complex or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing cell death of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate.Type: GrantFiled: January 16, 2013Date of Patent: March 24, 2015Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, David M. Goldenberg, Chien-Hsing Chang
-
Patent number: 8980824Abstract: Tubulysin compounds of the formula (I) where R1, R2, R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.Type: GrantFiled: February 11, 2014Date of Patent: March 17, 2015Assignee: Bristol-Myers Squibb CompanyInventors: Qiang Cong, Heng Cheng, Sanjeev Gangwar
-
Patent number: 8974792Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: GrantFiled: April 6, 2012Date of Patent: March 10, 2015Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Patent number: 8968741Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.Type: GrantFiled: February 6, 2013Date of Patent: March 3, 2015Assignee: Genentech, Inc.Inventors: Allen J. Ebens, Alane M. Gray, Wei-Ching Liang, Yan Wu, Shang-Fan Yu
-
Publication number: 20150056223Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD), including a conjugate prepared by covalently linking an insulinotropic peptide, a non-peptidyl polymer and an immunoglobulin Fc region. The composition of the present invention maintains the in-vivo activity of the peptide at a relatively high level, and remarkably increases the blood half-life, thereby preventing triglyceride accumulation which is a typical feature of non-alcoholic fatty liver disease. Ultimately, it can be desirably employed for the prevention and treatment of non-alcoholic fatty liver disease.Type: ApplicationFiled: March 8, 2013Publication date: February 26, 2015Applicant: HANMI SCIENCE CO., LTDInventors: Se Young Lim, Sung Hee Park, Ryoung Ae Shin, In Young Choi, Se Chang Kwon
-
Patent number: 8962805Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: GrantFiled: March 21, 2014Date of Patent: February 24, 2015Assignee: Ablynx N.V.Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
-
Publication number: 20150044229Abstract: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.Type: ApplicationFiled: August 20, 2014Publication date: February 12, 2015Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC.Inventors: Vijay K. Kuchroo, Laurent Monney, Jason L. Gaglia, Edward A. Greenfield, Gordon J. Freeman, Hanspeter Waldner
-
Publication number: 20150044237Abstract: New chimeric molecules involving in their structure, a combination of the extracellular domain (EC) of the FasL protein and a domain enabling oligomerisation of this Fas Ligand (FasL) EC domain, such as the Ig-like (so-called Ig in the following pages) domain of the gp190 receptor for the Leukemia Inhibitory Factor (LIF), or involving in their structure variants of the domains. Also, compositions including the chimeric molecule defined herein and the use of these chimeric molecules especially to trigger cytotoxic activity toward cells sensitive to FasL.Type: ApplicationFiled: October 26, 2012Publication date: February 12, 2015Applicant: Centre National de la Recherche ScientifiqueInventors: Jean-Luc Taupin, Sophie Daburon, Jean-Francois Moreau, Myriam Capone
-
Patent number: 8951532Abstract: The invention relates to the identification, sequencing, and isolation of an A25 bacteriophage lysin gene that expresses a protein involved in the lysis of bacterial cells during the phage life cycle. The invention further relates to methods for lysing certain bacteria using lysin, which are useful for example in a diagnostic procedure designed to detect these bacteria.Type: GrantFiled: January 25, 2011Date of Patent: February 10, 2015Assignee: Alere Scarborough, Inc.Inventors: Brion Mermer, William J. Palin, Nancy Turcotte
-
Patent number: 8945570Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.Type: GrantFiled: October 26, 2012Date of Patent: February 3, 2015Assignee: Agensys, Inc.Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
-
Patent number: 8945571Abstract: The present invention relates to immunoconjugates. In particular embodiments, the present invention relates to immunoconjugates comprising at least one single-chain effector moiety and two or more antigen binding moieties. In addition, the present invention relates to nucleic acid molecules encoding such immunoconjugates, vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.Type: GrantFiled: August 17, 2010Date of Patent: February 3, 2015Assignee: Roche GlyeArt AGInventors: Ekkehard Mössner, Ralf Jörg Hosse, Pablo Umaña, Michela Silacci-Melkko
-
Publication number: 20150030594Abstract: The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I? (SEQ ID NO: 1): or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor.Type: ApplicationFiled: July 21, 2014Publication date: January 29, 2015Applicant: NOVARTIS AGInventors: Jun YUAN, Frederic ZECRI, Philipp GROSCHE, Hongjuan ZHAO, Andrei GOLOSOV, Kayo YASOSHIMA, David Thomas PARKER, Eric PETERS, Aimee Richardson USERA, Shari Lynn CAPLAN, Aaron KANTER, Changgang LOU, Carla Guimaraes
-
Publication number: 20150030617Abstract: The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased half-life to provide more time for the therapeutic benefit.Type: ApplicationFiled: August 6, 2014Publication date: January 29, 2015Inventors: David Jenkins, Ming Lei, Andreas Loew, Li Zhou
-
Publication number: 20150023987Abstract: The invention described herein pertains to compounds and conjugates, to compositions, complexes and formulations comprising the compounds and/or conjugates, and to methods of use of the compounds, conjugates and their compositions, complexes and formulations in vaccines and vaccinations and generating immune responses.Type: ApplicationFiled: January 27, 2012Publication date: January 22, 2015Applicant: PURDUE RESEARCH FOUNDATIONInventor: Lawrence E. Hem
-
Publication number: 20150023988Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: January 22, 2015Applicant: AMGEN INC.Inventors: Justin K. MURRAY, Jerry Ryan HOLDER, Malgorzata WANSKA, Christopher M. TEGLEY, James R. FALSEY, Elizabeth M. DOHERTY, Leslie P. MIRANDA
-
Publication number: 20150023989Abstract: The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures.Type: ApplicationFiled: December 12, 2012Publication date: January 22, 2015Inventors: Hans-Georg Lerchen, Stefanie Hammer, Axel Harrenga, Charlotte Christine Kopitz, Carl Friedrich Nising, Anette Sommer, Beatrix Stelte-Luowig, Christoph Mahlert, Joachim Schuhmacher, Sven Golfier, Simone Greven, Sandra Bruder
-
Publication number: 20150017189Abstract: The invention provides methods for attaching drugs, dyes or radiolabels to bis-MTX. This method can be used to prepare bis-MTX analogs that can be used to deliver agents, such as nanoparticles, drugs, dyes or radiolabels, to cells.Type: ApplicationFiled: January 18, 2013Publication date: January 15, 2015Inventors: Carston R. Wagner, Jae Chul Lee, Sidath C. Kumarapperuma
-
Publication number: 20150010494Abstract: A method of preparing an oxidised polysaccharide-protein conjugate by oxidising a polysaccharide with an oxidising agent to form an oxidised polysaccharide and combining such oxidised polysaccharide with a protein. The oxidised polysaccharide is reacted with a protein to form a composition comprising a conjugate wherein the oxidised polysaccharide and the protein are conjugated via one or more imine bonds and wherein the oxidised polysaccharide comprises essentially no alpha-hydroxy aldehyde units. The conjugate may be used to provide sustained or latent activity of the protein.Type: ApplicationFiled: September 22, 2014Publication date: January 8, 2015Inventors: Gord Adamson, David Bell, Steven Brookes
-
Publication number: 20150010640Abstract: Disclosed herein are compositions and methods for the targeted delivery of therapeutic cells to a target tissue. In several embodiments, the therapeutic cells are captured by an antibody that is coupled to a magnetic particle, which is in turn coupled to an antibody directed against a specific marker expressed by a target tissue. In some embodiments, the therapeutic cells comprise the target tissue is damaged or diseased cardiac tissue. In several embodiments, in conjunction with an applied magnetic field, the methods, in combination with the compositions, yield enhanced delivery, of the therapeutic cells to the target tissue, thereby resulting in repair and/or regeneration of the target tissue. Also disclosed are methods for the non-invasive detection of immune responses to transplanted cells or organs.Type: ApplicationFiled: July 16, 2014Publication date: January 8, 2015Inventors: Eduardo Marban, Ke Cheng
-
Publication number: 20140377290Abstract: The present invention relates to a glucagon-like peptide-2 (GLP-2) conjugate comprising native GLP-2 or its derivative and an immunoglobulin Fc fragment being covalently linked via a non-peptidyl polymer, wherein the native GLP-2 or its derivative has a thiol group introduced at its C-terminal end, and one end of the non-peptidyl polymer is linked to an amino acid residue of the GLP-2 other than the N-terminal amino group thereof; a method for preparing the GLP-2 conjugate; a pharmaceutical composition comprising the same; and a method for treating or preventing intestinal disease, intestinal injury, or gastrosia by using the same. Since the GLP-2 conjugate of the present invention has a remarkably increased binding affinity to a GLP-2 receptor, it shows a prolonged in vivo half-life and an improved in vivo durability and stability.Type: ApplicationFiled: December 28, 2012Publication date: December 25, 2014Applicant: HANMI SCIENCE CO., LTD.Inventors: Seung Su Kim, Se Young Lim, Sung Youb Jung, Se Chang Kwon
-
Publication number: 20140369960Abstract: Novel biologically active compounds of the general formula (I) in which one of X and X? represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if X? represents a polymer, X-Q-W— together may represent an electron withdrawing group; and in addition, if X represents a polymer, X? and electron withdrawing group W together with the interjacent atoms may form a ring; each of Z1 and Z2 independently represents a group derived from a biological molecule, each of which is linked to A and B via an amine group; or Z1 and Z2 together represent a single group derived from a biological molecule which is linked to A and B via two amine groups; A is a C1-5 alkylene or alkenylene chain; and B is a bond or a C1-4 alkylene or alkenylene chain; are formed by conjugating a suitable polymer to a suitable biologically active molecule via amine groups in saiType: ApplicationFiled: July 28, 2014Publication date: December 18, 2014Inventors: Stephen James BROCCHINI, Antony Robert Godwin, Elisa Pedone, Ji-Won Choi, Sunil Shaunak
-
Publication number: 20140363452Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.Type: ApplicationFiled: July 2, 2014Publication date: December 11, 2014Inventors: Matthew David DOROSKI, Andreas MADERNA, Christopher John O'DONNELL, Chakrapani SUBRAMANYAM, Beth VETELINO, Russell George DUSHIN, Pavel STROP, Edmund Idris GRAZIANI
-
Patent number: 8906379Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.Type: GrantFiled: January 20, 2012Date of Patent: December 9, 2014Assignee: Genzyme CorporationInventor: James Stefano
-
Publication number: 20140356384Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.Type: ApplicationFiled: August 15, 2014Publication date: December 4, 2014Inventors: Jeffrey A. Hubbell, Stéphane Kontos, Karen Y. Dane
-
Publication number: 20140356383Abstract: The present invention relates to methods for the treatment of gastrointestinal cancers. In particular, the invention provides methods for treatment of a gastrointestinal cancer by administering an immunoconjugate comprising an anti-GCC antibody molecule in combination with a DNA damaging agent.Type: ApplicationFiled: February 27, 2014Publication date: December 4, 2014Inventor: Ole Petter Veiby
-
Publication number: 20140356421Abstract: An antibody-conjugated double-emulsion nanocapsule is provided. A linking group is introduced on the surface of a double-emulsion nanocapsule, which is composed of an oily shell enclosing an aqueous core, to link the double-emulsion nanocapsule with an antibody.Type: ApplicationFiled: April 24, 2014Publication date: December 4, 2014Applicant: National Chiao Tung UniversityInventors: Chih-Sheng Chiang, Shang-Hsiu Hu, San-Yuan Chen
-
Publication number: 20140348860Abstract: Disclosed is a medical device constructed and arranged for contact with a flow of blood or other bodily fluid of a patient and including an attached binding agent or a roughened surface that binds to pathogenic cells targeted for elimination from the blood or other bodily fluid. Also disclosed are methods for making and using the device.Type: ApplicationFiled: August 13, 2014Publication date: November 27, 2014Inventors: Julia E. Barbick, Andrew K. Hoffa, Tyler J. Bunch, Sean Chambers, Colleen Gemborys
-
Publication number: 20140348859Abstract: Compositions of and methods for making and using alpha-1 antitrypsin (AAT) fusion molecules or peptide derivatives thereof are disclosed. The compositions and methods relate to generating an AAT fusion molecule of use in pharmaceutically acceptable compositions to treat a subject in need of AAT therapy or treatment. Compositions and methods disclosed herein concern linking AAT or derivative thereof to an immune fragment.Type: ApplicationFiled: January 10, 2013Publication date: November 27, 2014Applicants: KONKUK UNIVERSITY, OMNI BIO PHARMACEUTICAL, INC., THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATEInventors: Soohyun Kim, Charles A. Dinarello, James D. Crapo
-
Patent number: 8894997Abstract: The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of influenza virus infections. In particular, these antibodies may neutralize or limit the replication of H1N1 influenza virus. Also disclosed are improved methods for producing such monoclonal antibodies.Type: GrantFiled: April 30, 2010Date of Patent: November 25, 2014Assignees: Vanderbilt University, Icahn School of Medicine at Mount SinaiInventors: James E. Crowe, Christopher F. Basler
-
Patent number: 8871908Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: GrantFiled: November 7, 2012Date of Patent: October 28, 2014Assignee: Rinat Neuroscience Corp.Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
-
Patent number: 8852605Abstract: The disclosure pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present disclosure also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.Type: GrantFiled: April 3, 2007Date of Patent: October 7, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Shousun Chen Szu, Zuzana Kossaczka, John B. Robbins
-
Publication number: 20140294762Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.Type: ApplicationFiled: April 7, 2014Publication date: October 2, 2014Applicant: Novo Nordisk A/SInventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, David James Hakes, Caryn L. Bowe, Xi Chen
-
Publication number: 20140294865Abstract: The invention relates to tumor therapy. In one aspect, the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by certain linkages, which are useful in the treatment of cancer. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates.Type: ApplicationFiled: March 9, 2012Publication date: October 2, 2014Applicant: HEIDELBERG PHARMA GMBHInventors: Werner Simon, Christian Lutz, Christoph Muller, Jan Anderl
-
Publication number: 20140294866Abstract: The present invention provides methods for treating disorders arising from hypogonadism by administering myostatin antagonists to subjects suffering from such disorders.Type: ApplicationFiled: June 19, 2014Publication date: October 2, 2014Inventors: Huiquan Han, Alexander DePaoli, John Zhao-Nian Lu, Jin Lin Wang